Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;333:1193 (9 December), doi:10.1136/bmj.38993.560984.BE (published 7 November 2006)
Jan Jelrik Oosterheert, research associate1, Marc J M Bonten, professor of infectious diseases1, Margriet M E Schneider, infectiologist1, Erik Buskens, associate professor of epidemiology2, Jan-Willem J Lammers, professor of pulmonology3, Willem M N Hustinx, infectiologist4, Mark H H Kramer, internist/haematologist5, Jan M Prins, infectiologist6, Peter H Th J Slee, internist7, Karin Kaasjager, internist8, Andy I M Hoepelman, professor of medicine1
1 Department of Internal Medicine and Infectious Diseases, University Medical Centre, PO Box 85500, 3508 GA Utrecht, Netherlands, 2 Julius Centre for Health Sciences and Primary Care, University Medical Centre, 3 Department of Pulmonology, University Medical Centre, 4 Department of Internal Medicine, Diakonessenhuis, Utrecht, 5 Department of Internal Medicine, Meander Medical Centre, Amersfoort, Netherlands, 6 Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and Aids, Academic Medical Centre, Amsterdam, Netherlands, 7 Department of Internal Medicine, St Antonius Hospital, Nieuwegein, Netherlands, 8 Department of Internal Medicine, Rijnstate Hospital, Arnhem, Netherlands
Correspondence to: A I M Hoepelman i.m.hoepelman{at}umcutrecht.nl
Design Multicentre randomised controlled trial.
Setting Five teaching hospitals and 2 university medical centres in the Netherlands.
Participants 302 patients in non-intensive care wards with severe community acquired pneumonia. 265 patients fulfilled the study requirements.
Intervention Three days of treatment with intravenous antibiotics followed, when clinically stable, by oral antibiotics or by 7 days of intravenous antibiotics.
Main outcome measures Clinical cure and length of hospital stay.
Results 302 patients were randomised (mean age 69.5 (standard deviation 14.0), mean pneumonia severity score 112.7 (26.0)). 37 patients were excluded from analysis because of early dropout before day 3, leaving 265 patients for intention to treat analysis. Mortality at day 28 was 4% in the intervention group and 6% in the control group (mean difference 2%, 95% confidence interval 3% to 8%). Clinical cure was 83% in the intervention group and 85% in the control group (2%, 7% to 10%). Duration of intravenous treatment and length of hospital stay were reduced in the intervention group, with mean differences of 3.4 days (3.6 (1.5) v 7.0 (2.0) days; 2.8 to 3.9) and 1.9 days (9.6 (5.0) v 11.5 (4.9) days; 0.6 to 3.2), respectively.
Conclusions Early switch from intravenous to oral antibiotics in patients with severe community acquired pneumonia is safe and decreases length of hospital stay by 2 days.
Trial registration Clinical Trials NCT00273676 [ClinicalTrials.gov] .
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses